drugset
drugset / Trial / NCT03875287

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

NCT03875287 ↗

Phase 1 Active not recruiting 35 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Astex Pharmaceuticals, Inc. · collabStand Up To Cancer · collab
NaSequentialOpen-labelOther

Summary

This is a phase 1 study of the combination of cedazuridine with decitabine in patients with solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal hypomethylation and toxicity (up to 35 patients total).

Timeline

Start
2019-04-17
Primary completion
2026-09-02
Completion
2027-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cedazuridine Small molecule 100 mg Oral
Subject Decitabine Small molecule 10 mg Oral
Subject Decitabine Small molecule 15 mg Oral
Subject Decitabine Small molecule 20 mg Oral
Subject Decitabine Small molecule 25 mg Oral

Indications

cancer